Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Oct 13, 2017
Clinical News

Biogen reports additional Spinraza data for SMA

BioCentury | Jun 2, 2017
Clinical News

EC approves Biogen's Spinraza for SMA

BioCentury | Apr 26, 2017
Clinical News

Spinraza regulatory update

BioCentury | Jan 27, 2017
Clinical News

Spinraza: Additional Ph III ENDEAR data

BioCentury | Dec 30, 2016
Clinical News

Spinraza regulatory update

BioCentury | Nov 11, 2016
Clinical News

Spinraza: Interim Ph III data

BioCentury | Nov 4, 2016
Clinical News

Nusinersen regulatory update

BioCentury | Oct 3, 2016
Clinical News

Nusinersen regulatory update

BioCentury | Sep 26, 2016
Company News

Biogen submits nusinersen NDA

Items per page:
1 - 10 of 13